Table 4

Parameter coefficients from multivariable analysis of predictors of quality of life, evaluated separately for each of the functioning and symptom scales in the IPTW-adjusted cohort

Variables included in each multivariable modelFunctioning scales*Symptom scales†
Global QoLPhysicalRoleEmotionalCognitiveSocialFatiguePain
Age at survey (years, reference is age 0)−0.08−0.63‡−0.41‡0.25‡0.13−
LEL and BMI category
 No LEL and BMI <30
 No LEL and BMI 30–39.9−6.52‡−5.27‡−2.89−2.61−1.92−2.02−0.32−1.00
 No LEL and BMI 40+−6.4210.97‡ −7.33−3.80−4.00−0.203.560.70
 LEL and BMI <30−6.94−4.2212.47‡ −7.320.41−4.54 10.03‡ 9.03
 LEL and BMI 30–39.918.13‡ 15.74‡ 12.64‡ −8.17‡10.18‡ 13.75‡ 18.83‡ 19.48‡
 LEL and BMI at 40+19.70‡ 33.08‡ 31.11‡ 13.24‡ 22.19‡ 30.66‡ 19.97‡ 29.26‡
History of diabetes at time of survey0.44−6.74‡−3.60−1.55−5.58‡−4.801.976.57‡
History of heart failure or congestive heart failure at time of survey6.25 −4.39−0.481.746.211.440.07−8.69
History of kidney disease or failure at time of survey16.60‡ −2.48−0.9114.12‡ 12.07‡ −3.82 13.86‡ 18.38‡
Therapy received as treatment for primary cancer or recurrence
 None (reference)00000000
 EBRT alone0.741.380.13−2.00−2.482.042.210.98
 Chemotherapy±EBRT0.28−4.44−3.15−5.4010.24‡ −3.755.832.23
Type of staging
 SLN biopsy (reference)00000000
  • QoL scores range from 0 to 100.

  • Bold indicates clinically meaningful difference (≥10 points).

  • *Higher functional scores indicate better functional well-being.

  • †Higher symptom scores indicate worse symptom.

  • ‡Statistically significant, p<0.05.

  • BMI, body mass index (kg/m2) at time of survey; EBRT, external beam radiation therapy; IPTW, inverse-probability of treatment weighting; LEL, lower extremity lymphedema; LND, lymphadenectomy; QoL, quality of life; SLN, sentinel lymph node.